China News Service, December 31 (Chen Jing and Shen Yan) Chromosomal diseases and single gene diseases are one of the important causes of birth defects in China.
The Obstetrics and Gynecology Hospital Affiliated to Fudan University disclosed on the 31st that experts from the hospital used integrated PGT platform technology to simultaneously block chromosome balanced translocation and single-gene disease, and the third-generation test-tube baby Yiyi (a pseudonym) was born successfully.
Xu Congjian, Dean of the Obstetrics and Gynecology Hospital of Fudan University, said in an interview on the 31st that this means that Shanghai experts have made breakthroughs in the field of reproductive blockade of genetic diseases.
He hopes that the new technology can benefit more patients with genetic diseases in the future, promote the progress of assisted reproductive technology, further reduce birth defects and improve the population's reproductive health.
It is understood that the pre-implantation genetic testing (PGT) technology commonly used in the industry has certain shortcomings: different indications require different testing technology platforms; even for the same indication, different disease types may be Different technology platforms are required, the operation is relatively complicated, and multiple different tests are required, which takes a long time, and lacks a unified universal PGT technology platform suitable for different indications and diseases.
Professor Sun Xiaoxi, deputy dean of the Shanghai Jiai Genetics and Infertility Clinic of the Obstetrics and Gynecology Hospital of Fudan University, explained to reporters vividly: “The integrated PGT technology platform is a bit like the “one network” in the reproductive genetic testing industry, which is the integration of different technical methods. The advantage of establishing a simple and efficient general-purpose testing platform will bring hope for more healthy and new lives to more families in need, strengthen the comprehensive prevention and treatment of birth defects, and help prenatal and postnatal care."
"Yiyi" mother Ms. Dong suffered two spontaneous abortions and one biochemical pregnancy around the age of 25.
After examination, it was found that Ms. Dong had a chromosome problem—a balanced translocation of chromosomes.
According to reports, balanced chromosomal abnormalities are an important factor leading to recurrent miscarriage and infertility in women, and balanced chromosomal translocations are the most common.
Ms. Dong and his wife also carry disease-causing mutations in related genes, and the child may have abnormalities in the inner ear and thyroid.
According to the hospital, once Ms. Dong becomes pregnant, the baby will have a 25% probability of becoming a patient and 50% as a carrier.
Ms. Dong and his wife came to the Obstetrics and Gynecology Hospital of Fudan University for treatment, hoping to give birth to a healthy child through PGT technology.
According to reports, Ms. Dong matched nine embryos through ovulation induction. After testing by the integrated PGT technology platform, one of the embryos neither carried a chromosomal balanced translocation nor a disease-causing mutation in a related gene. After the embryos were transplanted into Ms. Dong's uterus, they grew and developed smoothly and grew into a healthy "one by one" quack. The 4.1-kg baby has a score of 10 for "one to one" newborn, and the mother and child are healthy. (Finish)